Open AccessClinical perspectives and concerns of metformin as an anti‐aging drug
Author(s) -
Wang Chuyao,
Chen Bangwei,
Feng Qian,
Nie Chao,
Li Tao
Publication year - 2020
Publication title -
aging medicine
Language(s) - English
Resource type - Journals
ISSN - 2475-0360
DOI - 10.1002/agm2.12135
Subject(s) - metformin , longevity , observational study , medicine , drug , neurodegeneration , clinical trial , gerontology , bioinformatics , diabetes mellitus , pharmacology , biology , disease , endocrinology
Abstract As percentages of elderly people rise in many societies, age‐related diseases have become more prevalent than ever. Research interests have been shifting to delaying age‐related diseases by delaying or reversing aging itself. We use metformin as an entry point to talk about the important molecular and genetic longevity‐regulating mechanisms that have been extensively studied with it. Then we review a number of observational studies, animal studies, and clinical trials to reflect the clinical potentials of the mechanisms in lifespan extension, cardiovascular diseases, tumors, and neurodegeneration. Finally, we highlight remaining concerns that are related to metformin and future anti‐aging research.